CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing.
Newfield’s current exhibit - Private Eye: The Imagist Impulse in Chicago Art is open through December 5, 2021, and presents a fascinating look into this group of American contemporary artists
PureTech Founded Entity Vor Announces FDA Clearance of IND Application for VOR33
PureTech Founded Entity Vor Announces FDA Clearance of IND Application for VOR33
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (PureTech or the Company) is pleased to note that its Founded Entity, Vor Biopharma, a clinical-stage cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the companys Investigational New Drug (IND) application for VOR33, an eHSC therapy candidate being developed for the treatment of acute myeloid leukemia (AML). Vor plans to initiate a Phase 1/2a clinical trial for VOR33 in the first half of this year.